D. A. Roaquin

Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.

G. Lamont, M. P. Castaldi, Andrew X. Zhang, 2023, ACS chemical biology.

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Fiona Pachl, M. O’Connor, Glen Hawthorne, 2018, Experimental and Molecular Therapeutics.